Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment

This study has been withdrawn prior to enrollment.
(The investigator left the research center and the study was not carried out)
Sponsor:
Collaborator:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Information provided by:
UPECLIN HC FM Botucatu Unesp
ClinicalTrials.gov Identifier:
NCT00517231
First received: August 14, 2007
Last updated: July 6, 2015
Last verified: July 2015
  Purpose

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy.


Condition
Pulmonary Tuberculosis

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by UPECLIN HC FM Botucatu Unesp:

Enrollment: 0
Study Start Date: June 2005
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy. The propose of this work was to evaluate the production of IFN- γ in cell supernatants of peripheral blood mononuclear cells (PBMC) culture, TNF-α, IL-10 and TGF-b in cell supernatants of monocytes (MO) culture and biochemical (total proteins, albumin, globulin, α-1-acid glycoprotein and C-reactive protein) and hematological (VHS) serum parameters before and after 3 and 6 months of therapy

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of Mycobacterium tuberculosis infection

Exclusion Criteria:

  • all other granulomatous or neoplastic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517231

Sponsors and Collaborators
UPECLIN HC FM Botucatu Unesp
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Investigators
Principal Investigator: Jussara Marcondes-Machado, PHD Botucatu School of Medicine - Unesp
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00517231     History of Changes
Other Study ID Numbers: upeclin/HC/FMB-Unesp-pre02
Study First Received: August 14, 2007
Last Updated: July 6, 2015
Health Authority: Brazil: Ministry of Health

Keywords provided by UPECLIN HC FM Botucatu Unesp:
Pulmonary tuberculosis
Mycobacterium tuberculosis
Cytokines
Acute Phase Response
Treatment

Additional relevant MeSH terms:
Tuberculosis
Tuberculosis, Pulmonary
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Lung Diseases
Mycobacterium Infections
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on August 27, 2015